menu
    • menu
    [{"orgOrder":0,"company":"APOGEPHA ARZNEIMITTEL GMBH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Propiverine Hydrochloride","moa":"spasmolytic agents (papaverine type)","graph1":"Neurology","graph2":"Phase III","graph3":"APOGEPHA ARZNEIMITTEL GMBH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APOGEPHA ARZNEIMITTEL GMBH \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"APOGEPHA ARZNEIMITTEL GMBH \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"APOGEPHA ARZNEIMITTEL GMBH","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"HONG KONG","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Propiverine Hydrochloride","moa":"spasmolytic agents (papaverine type)","graph1":"Urology","graph2":"Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lee\\'s Pharmaceutical \/ APOGEPHA ARZNEIMITTEL GMBH","highestDevelopmentStatusID":"10","companyTruncated":"Lee\\'s Pharmaceutical \/ APOGEPHA ARZNEIMITTEL GMBH"}]

    Find Clinical Drug Pipeline Developments & Deals for (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride

    Menu

    (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            APOGEPHA ARZNEIMITTEL GMBH

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            APOGEPHA ARZNEIMITTEL GMBH

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propiverine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

                            Details : Propiverine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder, Neurogenic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2012

                            Lead Product(s) : Propiverine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lee's Pharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Lee's Pharmaceutical

                            Hong Kong arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propiverine Hydrochloride

                            Therapeutic Area : Urology

                            Study Phase : Phase III

                            Sponsor : APOGEPHA ARZNEIMITTEL GMBH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder

                            Details : Propiverine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder, Overactive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2012

                            Lead Product(s) : Propiverine Hydrochloride

                            Therapeutic Area : Urology

                            Highest Development Status : Phase III

                            Sponsor : APOGEPHA ARZNEIMITTEL GMBH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth